Brief: Xbiotech Announces First Patient Enrolled In Phase I Clinical Trial For Novel Arthritis Therapy Natrunix-Sq
26/01/2022 15:22
Jan 26 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES FIRST PATIENT ENROLLED IN PHASE I CLINICAL TRIAL FOR NOVEL ARTHRITIS
THERAPY
NATRUNIX-SQ
Source text for Eikon: ID:nGNE9XLcM5
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke